Skip to main content

Evolocumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 16, 2023.

Applies to evolocumab: subcutaneous solution.

Serious side effects of Evolocumab

Along with its needed effects, evolocumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking evolocumab:

Incidence not known

Other side effects of Evolocumab

Some side effects of evolocumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to evolocumab: subcutaneous solution.

General

The more commonly reported adverse reactions have included nasopharyngitis, upper respiratory tract infection, back pain, and injection site reactions.

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions (including rash, eczema, erythema, urticaria)

Postmarketing reports: Angioedema[Ref]

Cardiovascular

Common (1% to 10%): Hypertension[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, gastroenteritis, nausea (1.8%)[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Local

Common (1% to 10%): Injection site reaction (including erythema, pain, bruising)[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, myalgia, musculoskeletal pain, arthralgia (1.8%)[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness

Uncommon (0.1% to 1%): Neurocognitive events (0.2%)[Ref]

Other

Common (1% to 10%): Influenza, fatigue (1.6%)

Uncommon (0.1% to 1%): Contusion[Ref]

Respiratory

Common (1% to 10%): Influenza, fatigue (1.6%)

Uncommon (0.1% to 1%): Contusion[Ref]

Immunologic

Rare (less than 0.1%): Development anti-drug antibody

Postmarketing reports: Influenza-like illness[Ref]

Frequently asked questions

References

1. Product Information. Repatha (evolocumab). Amgen USA. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.